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Although human immunodeficiency virus-1 (HIV-1) infects
quiescent and proliferating CD41 lymphocytes, the virus repli-
cates poorly in resting T cells1–6. Factors that block viral replica-
tion in these cells might help to prolong the asymptomatic phase
of HIV infection7; however, the molecular mechanisms that
control this process are not fully understood. Here we show
that Murr1, a gene product known previously for its involvement
in copper regulation8,9, inhibits HIV-1 growth in unstimulated
CD41 T cells. This inhibition was mediated in part through its
ability to inhibit basal and cytokine-stimulated nuclear factor
(NF)-kB activity. Knockdown of Murr1 increased NF-kB activity
and decreased IkB-a concentrations by facilitating phospho-IkB-
a degradation by the proteasome. Murr1 was detected in CD41
T cells, and RNA-mediated interference of Murr1 in primary
resting CD41 lymphocytes increased HIV-1 replication. Through
its effects on the proteasome, Murr1 acts as a genetic restriction
factor that inhibits HIV-1 replication in lymphocytes, which
could contribute to the regulation of asymptomatic HIV infec-
tion and the progression of AIDS.
Murr1 is a highly conserved 190-amino-acid protein that does
not have any identifiable motifs, and a homozygous deletion in the
gene encoding canine Murr1 leads to copper toxicosis in Bedlington
terriers8. In this study, Murr1 was initially identified in a two-hybrid
screen by binding the X-linked inhibitor of apoptosis, a known
activator of NF-kB (refs 10, 11, and E.B., unpublished observations).
To study its effect on NF-kB, HIV-1 reporter plasmids with wild-
type or mutant (DkB) sites2 were co-transfected with control or
Murr1 expression plasmids in the different cell lines. Murr1 inhib-
ited both basal and tumour necrosis factor (TNF)-a-dependent
HIV-1 transcription from the wild-type but not the kB-mutant
reporter in Jurkat T-leukaemia and 293T renal epithelial cell lines
(Fig. 1a, left and middle panels). In contrast, Murr1 did not
substantially inhibit tumour growth factor-b-dependent transcrip-
tion in HepG2 cells, confirming its specificity (Fig. 1a, right panel).
The kB effect was dose-dependent and observed with other inducers
of NF-kB, including interleukin-1 (IL-1) and 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) (Fig. 1b). Murr1 modulated the
expression of endogenous kB-regulated genes: transfection into
293T cells decreased the endogenous cell-surface expression of
major histocompatibility complex (MHC) class I, in contrast to
CD9, which is independent of NF-kB (Fig. 1c).
Its site of action in the NF-kB signalling pathway was further
defined by co-transfection of different regulators with an NF-kB
reporter in Jurkat T cells. Whereas Murr1 inhibited both IKK-1- and
IKK-2-induced NF-kB activity (Fig. 1d, middle and right panels), it
failed to block RelA-mediated transcription (Fig. 1d, left panel),
indicating that Murr1 might interact downstream of the IkB
kinase signalosome. As determined by immunoprecipitation, co-
transfected haemagglutinin (HA)-tagged Murr1 and Myc-tagged
IKK-2 did not associate in vivo (Fig. 2a, lane 2, left panel). Although
IKK-1 also did not associate with Murr1 (data not shown), an
interaction between transfected HA-tagged Murr1 and endogenous
IkB-a was readily detected (Fig. 2a, lane 6). The ankyrin domain of
IkB-a was required for association with Murr1, as were amino acids
1–160 of Murr1 (Supplementary Fig. 1a).
A polyclonal antibody against Murr1 demonstrated the associ-
ation between endogenous Murr1 and IkB-a in vivo. RelA antibody
immunoprecipitated IkB-a, IkB-b and Murr1 (Fig. 2b, lane 10).
IkB-a antibody also pulled down RelA and Murr1 (Fig. 2b, lane 12),
but the IkB-b antibody did not precipitate Murr1 (Fig. 2b, lane 14),
suggesting that Murr1 interacted preferentially with the NF-kB–
IkB-a complex. This association was confirmed in vivo by confocal
microscopy with fluorescent fusion proteins (Supplementary
Fig. 1b), similarly to the pattern of RelA association with IkB-a12–14.
The physiological consequences of these interactions were deter-
mined by knockdown of endogenous Murr1 in 293T cells using
control and Murr1-specific short interfering RNA (siRNA)
duplexes. The specificity of two such siRNAs, Murr1-1 and
Murr1-2, directed to different Murr1 sequences, was first confirmed
by transfecting 293T cells with wild-type or mutant siRNAs along
with wild-type or mutant Murr1 complementary DNAs modified at
the siRNA target site (Supplementary Fig. 2). Transient transfection
of Murr1-specific siRNA duplexes downregulated endogenous Murr1
and IkB-a, had little effect on IkB-b, p65 or IKK-2 (Fig. 3a, left panel),
and increased kB-dependent reporter activity (Fig. 3a, right panel).
To investigate the mechanism of Murr1 action, 293T cells were
transfected with a control or Murr1 siRNA. Four days after
transfection, cells were treated with the proteasome inhibitor
MG132 for 2 h or with vehicle alone and stimulated with TNF-a.
Cells depleted of Murr1 showed a decrease in basal IkB-a (Fig. 3a)
and an increase and persistence of phospho-IkB-a in response to
stimulation with TNF-a (Fig. 3b, left panel). This effect was
observed in the absence of a proteasome inhibitor, MG132, but
not in its presence (Fig. 3b, right panel), indicating that Murr1
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Figure 1 Murr1 suppresses NF-kB-dependent activity from independent stimuli by acting
downstream of IkB kinase. a, Murr1 inhibits kB-dependent gene expression in Jurkat
T-leukaemia cells (left) or 293T human embryonic kidney cells (middle) transfected with
HIV (WT) or DkB-luciferase reporter (DkB) and Murr1 (solid bars) or vector plasmid (open
bars). HepG-2 cells (right) were transfected with p3TP-Lux reporter. Cells were treated
with the indicated cytokines after 24 h, and luciferase activity was measured at 36 h.
b, Murr1 inhibits NF-kB induced by IL-1 and TPA in 293 cells. c, Murr1 decreases the
expression of NF-kB-dependent endogenous class I MHC in 293T cells transfected with
HA–LacZ (left) or HA–Murr1 (middle) by flow cytometry for class I and CD9 in HA-positive
cells. The decrease in MHC class I expression is summarized (right). d, Murr1 blocks the
activation by IKK-1 and IKK-2 but does not inhibit RelA transactivation. Fold stimulation
(left) and expression (right) are shown. An average of three independent experiments in
triplicate, standardized for transfection efficiency, are shown (a, b, d).
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might act similarly to a proteasome inhibitor to enhance and sustain
phospho-IkB. Phospho-IkB-a is degraded by ubiquitin–protein
conjugates that require three enzymes, which participate in a
cascade of ubiquitin transfer reactions: a ubiquitin-activating
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin
ligase (E3). The specificity of protein ubiquitination and 26S
proteasome degradation is determined by the E3 enzymes15.
Skp1/Cul1/b-TrCP1 (F-Box) complexes constitute a class of E3
enzymes that are required for the degradation of phospho-IkB-
a16. The possible association of endogenous Murr1 with Skp1/Cul1/
b-TrCP1 (F-box) complexes was examined. As determined by
immunoprecipitation followed by western blotting, Murr1 inter-
acted biochemically with the Cul1 and not the Skp1 component of
the E3 ligase complex, in contrast to a denatured negative control
(Fig. 3c). Although Murr1 binds to common constituents of E3
ligase, it nevertheless showed specificity because knockdown did not
alter steady-state concentrations of b-catenin, the target of protea-
somal degradation of the Wnt signalling pathway (Fig. 3d). Taken
together, these results suggest that Murr1 blocked NF-kB activation
through its ability to interact with E3 ligase and inhibit the
proteasomal degradation of IkB.
To determine whether Murr1 was detectable in T cells, lympho-
cytes from normal healthy individuals were examined. Both CD4þ
and CD8þ cells expressed Murr1, with higher concentrations in
CD4þ cells (Fig. 4a), raising the possibility that Murr1 might affect
HIV-1 replication in these cells. This possibility was examined first
by transfection of Murr1 in primary T cells and compared with
another inhibitor of NF-kB activation, the IkB super-repressor
(IkB-SR). Expression of recombinant Murr1 or IkB-SR inhibited
HIV-1 replication in activated T cells similarly relative to controls
(Fig. 4b; P ¼ 0.02; paired t-test), indicating that Murr1 might
inhibit HIV-1 replication comparably to NF-kB inhibitors in
primary activated T cells. To determine its effect on HIV-1 replica-
tion in resting primary T cells, CD4þ cells from HIV-1-negative
donors were transfected with an siRNA for Murr1 (Murr1-1) or a
negative control. To identify transfected cells, siRNAs were mixed
with an unrelated fluorescent Cy3-labelled luciferase siRNA at a
ratio of 2:1, and more than 30% of cells displayed fluorescence. In
Murr1 siRNA-transfected cells, a maximum decrease in Murr1
protein concentration was achieved between 48 and 72 h after
electroporation, and these cells did not display T-cell activation
markers—CD69, CD25 and HLA-DR—at the time of HIV-1 infec-
tion (data not shown). Murr1 siRNA increased dose-dependent
HIV-1 replication in primary resting CD4þ T cells from three
separate cell donors (Fig. 4c; P ¼ 0.0007, 0.0024 and 0.0014,
respectively; paired t-test), implicating Murr1 in the regulation of
HIV infection in these cells.
Whereas HIV-1 entry into activated CD4þ lymphocytes leads to a
productive infection1, the virus remains latent in resting CD4þ
lymphocytes17, existing as a preintegration complex awaiting cell
stimulation, which facilitates the transition to productive replica-
tion3,4,6,7,18. The molecular mechanisms responsible for HIV-1
Figure 2 Murr1 associates with the NF-kB–IkB-a complex. a, Murr1 does not associate
with IKK-2 but interacts with endogenous IkB-a. Lysates from transfected 293T cells,
treated with lactacystin (10 mM) 16 h before harvesting, were immunoprecipitated (IP) as
indicated and immunoblotted with antibody against IKK-2 (left) or IkB-a (right).
b, Immunoprecipitation of Murr1–NF-kB–IkB-a in 293T cells with antibodies against
indicated proteins. IgH, immunoglobulin heavy chain.
Figure 3 Murr1 regulates IkB-a turnover through effects on proteasomal degradation.
a, Knockdown of Murr1 decreases cellular IkB-a and increases basal NF-kB activity in
293T cells transfected with control or Murr1 siRNAs, analysed by immunoblotting to the
indicated proteins at 48 h (left). Fold stimulation of the indicated co-transfected plasmids
is shown (right). b, Murr1 alters IkB-a phosphorylation in 293T cells transfected with
control or Murr1 siRNAs. At 90 h after transfection, cells were treated with vehicle (left) or
MG132 (right) for 2 h, followed by stimulation with TNF-a and immunoblotting for Murr1
and phospho-IkB-a (top) and quantification (bottom). c, Immunoprecipitation (IP) of
Skp1–Cul1–b-TrCP1 complexes in 293T cell extracts with antibodies against Murr1 or
Skp1, immunoblotted for Cul1, Skp1 or Murr1. d, Knockdown of Murr1 by Murr1-2 siRNA
compared with a negative control (GFP) does not alter b-catenin concentrations.
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latency are not well understood. Among the factors that can activate
HIV-1 replication are host transcription factors such as NF-kB
(ref. 2), epigenetic modifications at the site of integration19, prema-
ture termination of transcription due to the absence of sufficient
concentrations of Tat and NF-kB (refs 20, 21), and inefficient export
of RNAs for structural proteins5. The roles of these factors in resting
CD4þ T cells are inferred from cell culture experiments and affect
viral transcription, translation or RNA transport. Here we show
that Murr1 regulates IkB-a turnover, which inhibits the productive
HIV-1 infection of resting T lymphocytes. Expression of Murr1 in
activated HIV-infected T cells also inhibited virus replication,
indicating that it might also have a function in limiting the extent
of viral replication, or burst size. NF-kB is sequestered in the
cytoplasm by a 450-kDa IkB complex12,22–25 and, after activation
of T cells, phosphorylation of IkB-a (ref. 26) in this complex by two
inducible kinases, IKK-1 and IKK-2, leads to the subsequent
ubiquitination and degradation of IkB-a by the 26S proteasome27.
Degradation of IkB-a by the proteasome releases NF-kB, which then
translocates to the nucleus to stimulate the synthesis of genes
involved in immune activation. NF-kB enhances transcription
and subsequently recruits several transcriptional activators, includ-
ing positive transcription elongation factor b, which is ubiquiti-
nated and degraded by the proteasome28. Inhibition of proteasomal
activity by Murr1, after it rebounds from its initial degradation and
after this processive transcription complex has formed, could
subsequently stabilize it and enhance transcription. The protea-
some, through the ubiquitin E3 ligase complex, is also involved in
viral processing and the maturation of Gag29. Because Murr1
inhibits proteasomal degradation, it could further block HIV-1
infection by decreasing the proteasome-dependent degradation and
maturation of Gag-associated factors required for viral replication,
and although Murr1 acts selectively on the NF-kB and not the Wnt
signalling pathway (Fig. 3), it remains possible that it might yet
affect other such proteins degraded by the proteasome. Such an
example is APOBEC3G, shown recently to associate with a Cul5 E3
ligase31. Blocks to viral replication in resting lymphocytes, as well as
in cells containing latent provirus, might affect disease progression
and viral rebound after the discontinuation of anti-retroviral
therapy (reviewed in ref. 7). A more precise understanding of the
molecular regulation of these events might identify novel genetic
restriction factors, like Murr1, through which anti-viral drugs might
delay the progression of HIV-1 infection to AIDS. A
Methods
Plasmids, siRNA and cell transfections
The gene encoding chloramphenicol acetyltransferase (CAT) in HIV-LTR–CAT and
HIV-LTR-DkB–CAT2 was replaced with the luciferase gene from pGL3 basic (Promega) to
construct HIV-LTR–Luc and HIV-LTR-DkB–Luc. The HA-IkB-a SR, p3TP-Lux reporter,
green fluorescent protein (GFP)–RelA, pRK-Myc-IKK-1, pRK-Myc-IKK-2, p65 and IkB-a
cDNAs are described in Supplementary Methods, as are siRNA sequences and the cell
transfection techniques.
T-cell purification and transfection
To purify resting T cells, CD4þ T lymphocytes were isolated from Ficoll-purified
peripheral blood mononuclear cells (PBMCs) by negative selection with a CD4þ T-cell
isolation kit containing CD8, CD11b, CD16, CD19, CD36 and CD56 antibodies (Miltenyi
Biotech). CD25þ and HLA-DRþ cells were then removed from this population by using
CD69, CD25 and HLA-DR antibodies (Miltenyi Biotech) by negative selection. The purity
of the isolated resting T cells was assessed by fluorescence-activated cell sorting (FACS)
analysis for CD4, CD69, CD25 and HLA-DR (BD-Pharmingen); 95% of the cells were
CD4þ and there were less than 0.1% of activated T cells as defined by the presence of CD69,
CD25 or HLA-DR. Resting CD4þ T cells (107) were transfected with control or Murr1
siRNA (Dharmacon). For each transfection, 1.2 mM siRNA (800 nM unlabelled siRNA and
400 nM Cy3-labelled siRNA) was used. Transfections were performed with a 2:1 mixture of
unlabelled siRNA and Cy3 luciferase. To transfect the resting CD4þ T cells with siRNA, 107
cells were resuspended in 100 ml T-cell Nucleofector reagent and immediately
electroporated with the recommended protocol U-14 on the Nucleofector instrument
(Amaxa Biosystems). The electroporated cells were washed 4 h after transfection and
incubated in 1.5 ml RPMI and infected with HIV-1 48 h after electroporation. FACS
analysis was performed with CD69, CD25 and HLA-DR antibodies (BD Pharmingen) to
check the activation status of the cells at the time of infection. For plasmid transfections,
CD4þ T lymphocytes isolated from Ficoll-purified PBMCs by negative selection were
stimulated with phytohaemagglutinin (10 mg ml21) (Calbiochem) and 40 U ml21 IL-2
(Peprotech) for 24 h and maintained in 40 U ml21 IL-2 for 4 days. Cells were then washed
to remove IL-2, and 107 cells were resuspended in 100 ml T-cell Nucleofector reagent
containing 0.5 mg of the respective plasmids and immediately electroporated with
recommended protocol T-20 on the Nucleofector instrument. The electroporated cells
were washed 12 h after transfection and incubated in 1.5 ml of RPMI supplemented with
40 U ml21 IL-2 and infected with HIV-1 24 h after electroporation.
HIV-1 infection and flow cytometric analysis for expression of p24-Gag
At 48 h after siRNA transfection or 24 h after plasmid transfection, HIV-1 infection of
CD4þ T lymphocytes was performed in 96-well round-bottomed culture plates by
combining 40 ml virus stock with 20 ml CD4þ T lymphocytes (1.5 £ 105 cells). The
multiplicity of infection of undiluted virus was,1.0. After incubation for 2 h at 37 8C, cells
were washed twice and continued in culture with indinavir at 1 mM. CD4þ T lymphocytes
were harvested for intracellular p24-Gag staining 48 h after exposure to virus. In brief, cells
were stained with anti-CD4-PE and ethidium bromide monoazide (EMA) for 10 min.
EMA was cross-linked to the cells by exposure to a bright light source for 15 min. Cells were
washed once, fixed and permeabilized with Cytoperm/Cytofix (BD Pharmingen) for
Figure 4 Murr1 inhibits productive HIV-1 infection in CD4þ lymphocytes. a, Murr1
concentrations in CD4þ and CD8þ T cells shown by immunoblotting with Murr1 antisera
and reprobing with b-actin antibody. b, Murr1 inhibits HIV-1 replication in
phytohaemagglutinin/IL-2-stimulated human CD4þ cells transfected with plasmids
encoding HA–LacZ (control), HA–Murr1 or HA–IkB-SR, infected with HIV-1BaL
(p24 ¼ 75 ng ml21) 36 h later. HIV-1 replication was analysed 48 h after infection by
staining for intracellular p24. A representative of three independent HIV-1-negative
donors is shown (P ¼ 0.02, control versus Murr1). c, Murr1 siRNA-transfected resting
CD4þ T lymphocytes from three healthy donors show increased susceptibility to HIV-1
infection after transfection with siRNA for Murr1 (Murr1-1) compared with GFP (control).
Cy3 luciferase siRNA was mixed with siRNAs (2:1) to label transfected cells. Single-round
HIV-1 replication was measured in labelled cells at 48 h. The multiplicity of infection of
undiluted virus was ,1.0.
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20 min. Cells were then stained for p24 Gag (KC-57 fluorescein isothiocyanate (FITC);
Coulter) for 20 min and washed once in 1 £ Perm/wash buffer (BD Pharmingen). Cells in
each group were analysed by flow cytometry for intracellular HIV-1 p24 and CD4 after the
exclusion of dead cells by their affinity for EMA. For a detailed description of HIV-1
production, infection and flow cytometric analysis see ref. 30.
Antibodies, western blots and immunoprecipitations
Cell lysis for western blots and immunoprecipitations were performed in cell lysis buffer
(Cell Signal). Antibodies against b-actin (Sigma), His (Invitrogen), HA, HA-PE, p65,
IkB-a, IkB-b, Cul1, Skp1 (Santa Cruz), IKK1, IKK2, Ser-32-phospho IkB-a, b-catenin
(Cell Signal) and HLA Class1 FITC (Biosource) were used in flow cytometry,
immunoblotting and immunoprecipitations in accordance with the manufacturer’s
instructions. Polyclonal Murr1 antibody has been described previously9.
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In mammals, dosage compensation ensures equal X-chromo-
some expression between males (XY) and females (XX) by
transcriptionally silencing one X chromosome in XX embryos1.
In the prevailing view, the XX zygote inherits two active X
chromosomes, one each from the mother and father, and X
inactivation does not occur until after implantation2–6. Here,
we report evidence to the contrary in mice. We find that one X
chromosome is already silent at zygotic gene activation (2-cell
stage). This X chromosome is paternal in origin and exhibits a
gradient of silencing. Genes close to the X-inactivation centre
show the greatest degree of inactivation, whereas more distal
genes show variable inactivation and can partially escape silenc-
ing. After implantation, imprinted silencing in extraembryonic
tissues becomes globalized and more complete on a gene-by-gene
basis. These results argue that the XX embryo is in fact dosage
compensated at conception along much of the X chromosome.
We propose that imprinted X inactivation results from inheri-
tance of a pre-inactivated X chromosome from the paternal germ
line.
In mice, X-chromosome inactivation (XCI) takes on two lineage-
specific forms. Random XCI1, in which both X chromosomes have
an equal chance of being inactivated, occurs in the epiblast (embryo
proper). In contrast, imprinted XCI7 leads to paternal X-chromo-
some (XP) silencing in the extraembryonic tissues (placenta).
Although the imprint is set in gametes, classical studies support a
view in which both XP and XM (maternal X chromosome) are
transmitted to the zygote in an active form: the absence of a late-
replicating X chromosome in pre-implantation embryos2 suggests
equal X-transcriptional status, and bimodal distributions of enzy-
matic activities for two X-linked genes (Hprt3,4, Gla5) suggest twice
as much expression in XX as compared with XYembryos. Thus, the
prevailing view postulates that XX and XY embryos have a twofold
imbalance of X dosage until implantation, when XCI takes place for
the first time in the extraembryonic and embryonic lineages6,8–10.
However, some recent observations have not been explained easily11.
Studies of the X-linked Pgk1 (refs 12, 13) revealed that, whereas the
maternal allele is expressed during pre-implantation development,
the paternal allele is silent. Furthermore, one Xist allele is expressed
at high levels in pre-implantation embryos9, leading to the idea that
the X chromosomes may be transcriptionally distinct6,11. Indeed, the
maternal and paternal haplogenomes can behave differently in early
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